WallStreetZenWallStreetZen

NASDAQ: CAI
Caris Life Sciences Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for CAI

Based on 7 analysts offering 12 month price targets for Caris Life Sciences Inc

Min Forecast
$26.00-20.85%
Avg Forecast
$31.57-3.89%
Max Forecast
$38.00+15.68%

Should I buy or sell CAI stock?

Based on 8 analysts offering ratings for Caris Life Sciences Inc.

Buy
Strong Buy
4 analysts 50%
Buy
1 analysts 12.5%
Hold
3 analysts 37.5%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%
Although CAI's forecast from analysts indicates a "Buy", our proven Zen Rating quant model rates CAI as a "Hold". Stocks with a Zen Rating of Hold have had an average return of +5.11% per year. Learn More

Be the first to know when Wall Street analysts revise their CAI stock forecasts and price targets.

CAI stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2026-10-27
lockedlocked$00.00+00.00%2026-10-19
lockedlocked$00.00+00.00%2026-10-14Find Out Why
lockedlocked$00.00+00.00%2026-10-13Find Out Why
lockedlocked$00.00+00.00%2026-09-09
Evercore ISI Group
Top 10%
91
BuyMaintains$26.00-20.85%2026-08-06
Wolfe Research
Top 24%
77
HoldAssumesN/AN/A2026-06-02
Citigroup
Top 12%
89
Strong BuyMaintains$28.00-14.76%2026-05-08

1 of 1

Forecast return on equity

Is CAI forecast to generate an efficient return?

Company
38.59%
Industry
14.98%
Market
172.55%
CAI's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is CAI forecast to generate an efficient return on assets?

Company
18.57%
Industry
21.21%
CAI is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

CAI earnings per share forecast

What is CAI's earnings per share in the next 3 years based on estimates from 15 analysts?

Avg 1 year Forecast
$0.13-92.57%
Avg 2 year Forecast
$0.40-76.41%
Avg 3 year Forecast
$0.57-66.58%
CAI's earnings are forecast to... subscribe to Premium to read more.
Forecast High Earnings Growth Forecast

CAI revenue forecast

What is CAI's revenue in the next 3 years based on estimates from 15 analysts?

Avg 1 year Forecast
$1.0B+5.09%
Avg 2 year Forecast
$1.2B+24.8%
Avg 3 year Forecast
$1.4B+45.11%
CAI's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

CAI earnings growth forecast

How is CAI forecast to perform vs Biotechnology companies and vs the US market?

Company
-29.79%
Industry
12.77%
Market
32.33%
CAI's earnings are forecast to... subscribe to Premium to read more.
Forecast Earnings Growth vs Industry Forecast
CAI's earnings are forecast to... subscribe to Premium to read more.
Forecast Earnings Growth vs Market Forecast
CAI's earnings are forecast to... subscribe to Premium to read more.
Forecast Earnings Growth vs Savings Rate Forecast

CAI revenue growth forecast

How is CAI forecast to perform vs Biotechnology companies and vs the US market?

Company
13.18%
Industry
29.34%
Market
12.56%
CAI's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
CAI's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

CAI vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
CAI$32.85$31.57-3.89%Buy
TGTX$60.75$64.00+5.35%Buy
MDGL$396.32$682.30+72.16%Strong Buy
PTGX$140.24$173.20+23.50%Strong Buy
PCVX$60.81$117.20+92.73%Strong Buy
View Top Biotech Stocks

Caris Life Sciences Stock Forecast FAQ

Is Caris Life Sciences Stock a good buy in 2026, according to Wall Street analysts?

The consensus among 8 Wall Street analysts covering (NASDAQ: CAI) stock is to Buy CAI stock.

Out of 8 analysts, 4 (50%) are recommending CAI as a Strong Buy, 1 (12.5%) are recommending CAI as a Buy, 3 (37.5%) are recommending CAI as a Hold, 0 (0%) are recommending CAI as a Sell, and 0 (0%) are recommending CAI as a Strong Sell.

If you're new to stock investing, here's how to buy Caris Life Sciences stock.

What is CAI's earnings growth forecast for 2026-2028?

(NASDAQ: CAI) Caris Life Sciences's forecast annual earnings growth rate of -29.79% is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 12.77%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 32.33%.

Caris Life Sciences's earnings in 2026 is $105,135,000.On average, 15 Wall Street analysts forecast CAI's earnings for 2026 to be $35,691,772, with the lowest CAI earnings forecast at $16,616,597, and the highest CAI earnings forecast at $59,344,989. On average, 15 Wall Street analysts forecast CAI's earnings for 2027 to be $113,348,929, with the lowest CAI earnings forecast at $27,694,328, and the highest CAI earnings forecast at $154,890,421.

In 2028, CAI is forecast to generate $160,570,585 in earnings, with the lowest earnings forecast at $55,388,656 and the highest earnings forecast at $231,445,457.

What is CAI's revenue growth forecast for 2026-2028?

(NASDAQ: CAI) Caris Life Sciences's forecast annual revenue growth rate of 13.18% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 29.34%, and while it is forecast to beat the US market's average forecast revenue growth rate of 12.56%.

Caris Life Sciences's revenue in 2026 is $989,605,000.On average, 15 Wall Street analysts forecast CAI's revenue for 2026 to be $293,898,993,440, with the lowest CAI revenue forecast at $278,107,574,446, and the highest CAI revenue forecast at $307,463,562,368. On average, 15 Wall Street analysts forecast CAI's revenue for 2027 to be $349,005,054,710, with the lowest CAI revenue forecast at $324,984,463,900, and the highest CAI revenue forecast at $379,525,334,798.

In 2028, CAI is forecast to generate $405,806,687,096 in revenue, with the lowest revenue forecast at $376,134,192,566 and the highest revenue forecast at $441,413,680,532.

What is CAI's forecast return on assets (ROA) for 2026-2029?

(NASDAQ: CAI) forecast ROA is 18.57%, which is lower than the forecast US Biotechnology industry average of 21.21%.

What is CAI's Price Target?

According to 7 Wall Street analysts that have issued a 1 year CAI price target, the average CAI price target is $31.57, with the highest CAI stock price forecast at $38.00 and the lowest CAI stock price forecast at $26.00.

On average, Wall Street analysts predict that Caris Life Sciences's share price could fall to $31.57 by Oct 27, 2027. The average Caris Life Sciences stock price prediction forecasts a potential downside of 3.89% from the current CAI share price of $32.85.

What is CAI's Earnings Per Share (EPS) forecast for 2026-2028?

(NASDAQ: CAI) Caris Life Sciences's current Earnings Per Share (EPS) is $1.70. On average, analysts forecast that CAI's EPS will be $0.13 for 2026, with the lowest EPS forecast at $0.06, and the highest EPS forecast at $0.21. On average, analysts forecast that CAI's EPS will be $0.40 for 2027, with the lowest EPS forecast at $0.10, and the highest EPS forecast at $0.55. In 2028, CAI's EPS is forecast to hit $0.57 (min: $0.20, max: $0.82).

What is CAI's forecast return on equity (ROE) for 2026-2029?

(NASDAQ: CAI) forecast ROE is 38.59%, which is considered strong.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.